Cooperative Agreement R41CA217294

Federal Project Grant Award Summary Gigamune, Inc. received an $800,000 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) on September 15, 2025, with a completion date of August 31, 2026. Under this award, the company, led by Principal Investigator David Scott Johnson, Ph.D., is developing a novel lentiviral vector platform for enhanced in vivo delivery of T cell receptors (TCRs) as a cell therapy approach for Stage IV...

This $999,960 Project Grant award from the National Cancer Institute's (CFDA 93.395) Cancer Treatment Research program supports the development of LNS8801, a small molecule therapeutic for cutaneous melanoma patients who cannot tolerate immunotherapy. The funding will enable Linnaeus Therapeutics Inc. to advance LNS8801 through human clinical trials, building on preclinical work that has demonstrated LNS8801's antitumor efficacy and safety profile. LNS8801 is an orally deliverable, small...

Federal Grant Award Summary Yale University received a $610,637 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026 through March 31, 2031. The award supports the development and preclinical evaluation of a versatile drug delivery platform utilizing bioadhesive and non-adhesive biodegradable nanoparticles engineered for selective locoregional delivery of cytotoxic and immune conditioning agents to advanced...

Federal Grant Award Summary Emory University received a $1.42M Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2025, through March 31, 2030. This R01 research grant supports a translational research initiative investigating neoadjuvant combination immunotherapy for melanoma treatment. The research team, led by Dr. Paulos (T cell immunologist) and Dr. Lesinski (translational scientist), will conduct...

Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the Regents of the University of Michigan a $660,808 Project Grant under the Cancer Biology Research program (CFDA 93.396) to investigate the durability and functional role of tissue-resident memory T cells (TRM) in melanoma immunotherapy response and long-term survival. The award, obligated on April 7, 2026, with a completion date of March 31, 2031, supports research examining how TRM cells—specifically a subset...

This Project Grant award from the National Institutes of Health's National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $630,781 to The Johns Hopkins University to develop lipid nanoparticle (LNP) and microgel formulations capable of programming Th1/Th2 immune responses for cancer immunotherapy. The key objectives are to: (1) develop mRNA LNP formulations that can elicit dual or biased Th1 and/or Th2 immune responses using machine learning-guided screening; (2) engineer...

This Cooperative Agreement award from the National Cancer Institute, a division of the Department of Health and Human Services, provides $380,509 under the Cancer Biology Research program to The Trustees of Columbia University in New York. The award supports research to elucidate the molecular drivers of melanoma liver metastasis and associated resistance to immunotherapies. Specifically, the researchers will characterize a novel preclinical mouse model that recapitulates genomic and...

This federal Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $959,882.00 to The Regents of the University of California, San Francisco (UCSF) to establish and overcome the mechanisms of liver metastasis-induced systemic tumor immune tolerance and immunotherapy resistance in melanoma. The 3-year research project aims to investigate fundamental biological processes and develop new therapeutic approaches to enhance the...

This $379,981 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop a localized cancer immunotherapy using particle-anchored cytokines for prolonged intratumoral retention. The primary objectives are to: (I) develop liposome-anchored cytokines with extended tumor retention and minimal systemic leakage, and (II) elucidate the mechanisms by which particle-anchored cytokines elicit durable anti-tumor immunity to improve efficacy in poorly...

This Project Grant award of $668,038.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports Drexel University's research on "BIOMIMETIC NANOPARTICLE-MEDIATED DELIVERY OF IMMUNOMODULATING NUCLEIC ACIDS AS A STRATEGY TO ANTICIPATE MELANOMA DRUG RESISTANCE." The 3-year project aims to develop innovative nanoparticle-based therapies to overcome drug resistance in melanoma treatment. As a private research university, Drexel has a...